Complementary Initiatives from the NIDDK to Advance Kidney Health

Norton, Jenna M.; Ketchum, Christian J.; Narva, Andrew S.; Star, Robert A.; Rodgers, Griffin P.

doi:10.2215/cjn.02120217

Cited by 16 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acknowledging several of the research needs, challenges, and issues identified at this workshop, the NIDDK has committed resources to the Kidney Precision Medicine Project (KPMP) for 2017, which will address many of these goals (Funding Opportunity Announcement Numbers: RFA-DK-16-026, RFA-DK-16-027, RFA-DK-16-028) (34). The KPMP will obtain kidney biopsy samples from patients with AKI (and CKD) under the highest ethical and safety standards.…”

Section: A Clinical Research Network: a Potential Solutionmentioning

confidence: 99%

“…These tissue samples will then be interrogated to determine disease subgroups, generate a kidney tissue atlas that will catalog the various cell types and interstitial components within the kidney, and elucidate relevant pathways to yield promising drug targets. Rapid and unimpeded data sharing with the entire AKI research community will be a key priority, and the NIDDK will regularly solicit proposals for ancillary studies to the KPMP to ensure that KPMP samples generate the maximum benefit to advance AKI research (34). Human targets and pathways identified by KPMP and other future efforts will need to Figure 3.…”

Section: A Clinical Research Network: a Potential Solutionmentioning

confidence: 99%

See 1 more Smart Citation

Overcoming Translational Barriers in Acute Kidney Injury

Żuk

Palevsky

Fried

et al. 2018

CJASN

Self Cite

View full text Add to dashboard Cite

AKI is a complex clinical condition associated with high mortality, morbidity, and health care costs. Despite improvements in methodology and design of clinical trials, and advances in understanding the underlying pathophysiology of rodent AKI, no pharmacologic agent exists for the prevention or treatment of AKI in humans. To address the barriers that affect successful clinical translation of drug targets identified and validated in preclinical animal models of AKI in this patient population, the National Institute of Diabetes and Digestive and Kidney Diseases convened the "AKI Outcomes: Overcoming Barriers in AKI" workshop on February 10-12, 2015. The workshop used a reverse translational medicine approach to identify steps necessary to achieve clinical success. During the workshop, breakout groups were charged first to design feasible, phase 2, proof-of-concept clinical trials for delayed transplant graft function, prevention of AKI (primary prevention), and treatment of AKI (secondary prevention and recovery). Breakout groups then were responsible for identification of preclinical animal models that would replicate the pathophysiology of the phase 2 proof-of-concept patient population, including primary and secondary end points. Breakout groups identified considerable gaps in knowledge regarding human AKI, our understanding of the pathophysiology of AKI in preclinical animal models, and the fidelity of cellular and molecular targets that have been evaluated preclinically to provide information regarding human AKI of various etiologies. The workshop concluded with attendees defining a new path forward to a better understanding of the etiology, pathology, and pathophysiology of human AKI.

show abstract

Section: A Clinical Research Network: a Potential Solutionmentioning

confidence: 99%

Section: A Clinical Research Network: a Potential Solutionmentioning

confidence: 99%

Overcoming Translational Barriers in Acute Kidney Injury

Żuk

Palevsky

Fried

et al. 2018

CJASN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several recent NIDDK projects, described previously (8,9), are intended to improve our understanding of human kidney biology, physiology, and disease [e.g., Kidney Precision Medicine Project, (Re)building a Kidney] and treatment options (pragmatic trials). Just as importantly, these efforts are intended to attract the best and brightest investigatorsfrom all career stages and communities-into kidney research.…”

Section: Attract Top Talent With Innovative Sciencementioning

confidence: 99%

Rebuilding the Pipeline of Investigators in Nephrology Research in the United States

Norton

Ketchum

Rankin

et al. 2018

CJASN

Self Cite

View full text Add to dashboard Cite

“…Starting in 2017, the CJASN will feature an annual update on the funding priorities and initiatives in patient-oriented research by the NIDDK. In the inaugural article in this issue, Norton et al (2) provide perspectives on three recent areas of focus by the agency-precision medicine, pragmatic trials, and health information technology.…”

mentioning

confidence: 99%

Perspectives on Funding Initiatives in Clinical Research in Kidney Disease in the United States

Mehrotra

2017

CJASN

View full text Add to dashboard Cite

Complementary Initiatives from the NIDDK to Advance Kidney Health

Cited by 16 publications

References 13 publications

Overcoming Translational Barriers in Acute Kidney Injury

Overcoming Translational Barriers in Acute Kidney Injury

Rebuilding the Pipeline of Investigators in Nephrology Research in the United States

Perspectives on Funding Initiatives in Clinical Research in Kidney Disease in the United States

Contact Info

Product

Resources

About